SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 2,629.98 |
Enterprise Value ($M) | 2,187.65 |
Book Value ($M) | 660.94 |
Book Value / Share | 5.54 |
Price / Book | 3.98 |
NCAV ($M) | 427.93 |
NCAV / Share | 3.59 |
Price / NCAV | 6.15 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | 0.21 |
Return on Assets (ROA) | 0.30 |
Return on Equity (ROE) | 0.37 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 4.92 |
Current Ratio | 5.11 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 539.00 |
Assets | 772.01 |
Liabilities | 111.07 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | 0.00 |
Net Income | 0.00 |
Earnings Per Share Basic And Diluted | n/a |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 0.00 |
Cash from Investing | 0.00 |
Cash from Financing | 0.00 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Flynn James E | |||
13G/A | BlackRock, Inc. | 16.00 | 0.00 | |
13G/A | State Street Corp | 4.80 | -16.24 | |
13G/A | Vanguard Group Inc | 6.68 | 5.20 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
145,404 | 696,594 | 20.87 | |
165,284 | 622,874 | 26.54 | |
105,544 | 485,543 | 21.74 | |
185,344 | 728,899 | 25.43 | |
(click for more detail) |